Our expanded PhysioMimix® Drug-induced Iiver injury (DILI) Contract Research Service, now features two new preclinical species models, Rat and Dog Liver-on-a-chip, for comparative cross-species DILI studies to improve IVIVE and de-risk development pipelines.

PhysioMimix cross-species DILI assays deliver clarity, confidence, speed, and ethical responsibility in preclinical drug development. Choose this approach to improve your in vitro to in vivo extrapolation (IVIVE) capabilities and confidently build more robust safety profiles that facilitate preclinical and clinical transition by:

• Predicting interspecies differences early to inform in vivo study design & reduce unnecessary animal use
• Identifying the mechanism of human DILI to address the cause
• Mitigating the risk of late-stage conflicting data or drug misclassification
• Providing clarity regarding which in vivo species is more human predictive to alleviate delays.